Hanmi Science Co., Ltd. (KRX:008930)
South Korea
· Delayed Price · Currency is KRW 37,200
-2,200 (-5.58%)
At close: Mar 9, 2026
Hanmi Science Revenue
Hanmi Science had revenue of 362.10B KRW in the quarter ending September 30, 2025, with 7.12% growth. This brings the company's revenue in the last twelve months to 1.34T, down -0.06% year-over-year. In the year 2024, Hanmi Science had annual revenue of 1.28T with 2.85% growth.
Revenue (ttm)
1,342.91B
Revenue Growth
-0.06%
P/S Ratio
1.88
Revenue / Employee
2.82B
Employees
476
Market Cap
2,518.95B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1,283.43B | 35.53B | 2.85% |
| Dec 31, 2023 | 1,247.91B | 201.85B | 19.30% |
| Dec 31, 2022 | 1,046.05B | 95.89B | 10.09% |
| Dec 31, 2021 | 950.16B | 92.78B | 10.82% |
| Dec 31, 2020 | 857.38B | 40.76B | 4.99% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,556.97B |
| Celltrion | 3,895.99B |
| ALTEOGEN | 202.18B |
| Sam Chun Dang Pharm. | 220.74B |
| SK bioscience | 624.03B |
| ST Pharm | 318.32B |
| Hugel | 425.10B |
| Hanall Biopharma | 154.05B |